Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...
Binswanger's disease, also known as subcortical leukoencephalopathy and subcortical arteriosclerotic encephalopathy, [1] is a form of small-vessel vascular dementia caused by damage to the white brain matter. [2] White matter atrophy can be caused by many circumstances including chronic hypertension as well as old age. [3]
Sugimoto was born as the eighth child among nine children in a downtown section of Tokyo in 1943, and joined Eisai, a Japanese pharmaceutical company. [3] While working for Eisai, he graduated from Chuo University in 1969 and obtained his doctorate in pharmacology at Hiroshima University in 2002. [3] In 2003, he retired from Eisai, and became ...
Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. [24] The UK National Institute for Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia.
Medical condition Dementia with Lewy bodies Other names Diffuse Lewy body disease, dementia due to Lewy body disease Microscopic image of a Lewy body (arrowhead) in a neuron of the substantia nigra ; scale bar=20 microns (0.02 mm) Specialty Neurology, psychiatry Symptoms Dementia, abnormal behavior during REM sleep, fluctuations in alertness, visual hallucinations, parkinsonism Usual onset ...
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, [2] and is the cause of 60–70% of cases of dementia. [2][15] The most common early symptom is difficulty in remembering recent events. [1] As the disease advances, symptoms can include problems with language, disorientation (including ...
Aducanumab is a monoclonal IgG1 antibody that binds to the amyloid beta protein at amino acids 3–7, which is posited to result in slowing the progression of Alzheimer's disease. [ 5 ] The mechanism is based on the amyloid hypothesis, which posits that amyloid proteins cause Alzheimer's disease, hence removing amyloid should slow the ...
Molar mass. 145089.74 g·mol −1. Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [ 1 ][ 2 ] Donanemab was developed by Eli Lilly and Company. [ 3 ][ 4 ] The most common side effects include amyloid-related imaging abnormalities and headache.